Moroctocog Alfa

Summary

Moroctocog Alfa (CHEMBL2109137) is an approved protein; indicated across 1 condition including hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109137
Name	Moroctocog Alfa
Type	Protein
Max phase	4

Also known as: Moroctocog alfa, Refacto, Refacto af, Refacto-af, Xyntha, MOROCTOCOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	6
Not specified	3
PHASE4	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00092976	PHASE4	COMPLETED	Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
NCT00168051	PHASE4	WITHDRAWN	Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
NCT00037544	PHASE3	COMPLETED	Study Evaluating ReFacto AF in Severe Hemophilia A
NCT00038935	PHASE3	COMPLETED	Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
NCT00141843	PHASE3	COMPLETED	Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
NCT00243659	PHASE3	COMPLETED	Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
NCT00759655	PHASE3	TERMINATED	Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age
NCT00868530	PHASE3	COMPLETED	Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
NCT02888223	PHASE1	UNKNOWN	Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
NCT04060836	PHASE1	UNKNOWN	Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
NCT00195442	Not specified	COMPLETED	Study Evaluating Refacto For Pharmacovigilance
NCT01959919	Not specified	COMPLETED	Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO
NCT02718677	Not specified	WITHDRAWN	Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).